Distinguished in Pantothenate Kinase-Associated Neurodegeneration

Susanne A. Schneider

Arnold Heller Str 3, 
Kiel, SH, DE 
Distinguished in Pantothenate Kinase-Associated Neurodegeneration
Arnold Heller Str 3, 
Kiel, SH, DE 
OverviewLocationsClinical Research

Overview

Susanne Schneider practices in Kiel, Germany. Ms. Schneider is rated as a Distinguished expert by MediFind in the treatment of Pantothenate Kinase-Associated Neurodegeneration. Her top areas of expertise are Hallervorden-Spatz Disease, Pantothenate Kinase-Associated Neurodegeneration, Chorea, Deep Brain Stimulation, and Cataract Removal.

Her clinical research consists of co-authoring 131 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles in the study of Pantothenate Kinase-Associated Neurodegeneration.

Gender
Female

Locations

Arnold Heller Str 3, Kiel, SH 24105, Germany
Other Locations
Ratzeburger Allee 160, Luebeck, SH 23538, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: N-Acetyl-L-Cysteine
Study Phase: Phase 2
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Enrollment Status: Completed
Publish Date: November 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Enrollment Status: Terminated
Publish Date: June 16, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

131 Total Publications

Current Perspectives and Practices in Infection-Related Movement Disorders (IRMD): Insights from a Survey of Members of the International Parkinson and Movement Disorder Society.
Current Perspectives and Practices in Infection-Related Movement Disorders (IRMD): Insights from a Survey of Members of the International Parkinson and Movement Disorder Society.
Journal: Movement disorders clinical practice
Published: May 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Schneider's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 45 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile